BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX Molecular Testing System

BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) BDX, and Lab21 announced today a collaboration to develop a state-of-the-art molecular diagnostic assay to detect the life-threatening Aspergillus fungus using the new fully automated BD MAX™ Molecular Testing System. "The potential to detect Aspergillus in blood using real-time polymerase chain reaction is a topic of great interest to clinicians since it offers faster, more sensitive and more accurate diagnostic and screening strategies for the early and definitive detection of aspergillosis," said Graham Mullis, CEO of Lab21.